Irritable Bowel Syndrome (IBS) is a widespread disease with variable symptoms that have an important impact on the quality of life. Despite the prevalence of IBS, its etiology and pathophysiology are still to be fully understood, but immune response is known to be involved. In this study, we investigated the variation of two specific cytokines, B-cell activating factor (BAFF) and platelet-activating factor (PAF), the levels of food-specific IgG and the symptom severity, using Irritable Bowel Syndrome—Symptom Severity Score (IBS-SSS), following a personalized and unrestricted-calorie diet. We enrolled 30 subjects with diagnosis of IBS, according to Rome-IV criteria, whose inflammatory markers were measured at baseline and after 6 weeks of dietary intervention. The subjects were monitored in a general practice outpatient setting and nutritional advice was offered remotely via two telephone sessions with a nutritionist. BAFF and PAF values did not differ between baseline and end of study, both in compliant (C) and non-compliant (NC) subjects. IgG levels significantly decreased only in compliant subjects: 37.32 (23.24–93.67) IU/mL; 27.9 (7.56–93.96) IU/mL (p = 0.02) and in non-compliant went from 51.83 (13.17–113.1) IU/mL to 44.06 (4.96–255.4) IU/mL (p = 0.97, ns). IBS-SSS significantly decreased in both compliant subjects, from 245 (110–480) to 110 (0–140) (p < 0.0001), and non compliant subjects, from 250 (155–370) to 100 (7–220) (p < 0.0001). Comparing IBS-SSS between week 3 and week 6, only compliant subjects had a significant reduction, from 155 (50–355) to 110 (0–140) (p = 0.005), versus non-compliant, from 115 (35–315) to 100 (7–220) (p = 0.33, ns). These findings support the rapid efficacy and suitability of a personalized dietetic intervention with outside consultation in IBS. Trial registration: ClinicalTrials.gov ID NCT04348760 Registered April 15, 2020 (retrospectively registered) https://clinicaltrials.gov/show/NCT04348760

中文翻译：

---

特定食物的血清IgG和在肠易激综合征（IBS）中进行六周的个性化，无热量饮食的症状减少

肠易激综合症（IBS）是一种广泛存在的疾病，其症状多种多样，对生活质量产生重要影响。尽管IBS盛行，但其病因和病理生理学仍需充分了解，但已知涉及免疫应答。在这项研究中，我们使用肠易激综合征（症状严重程度评分）研究了B细胞活化因子（BAFF）和血小板活化因子（PAF）这两种特异性细胞因子，食物特异性IgG的水平和症状严重程度的变化。 （IBS-SSS），遵循个性化且无热量的饮食。根据罗马-IV标准，我们招募了30名诊断为IBS的受试者，他们的炎症标志物是在基线和饮食干预6周后测量的。在普通科门诊中对受试者进行监测，并通过与营养师的两次电话会议远程提供营养建议。基线（B）和研究结束之间的BAFF和PAF值无差异，无论是符合（C）还是不符合（NC）受试者。IgG水平仅在符合条件的受试者中显着降低：37.32（23.24–93.67）IU / mL；27.9（7.56-93.96）IU / mL（p = 0.02），不合规时从51.83（13.17-113.1）IU / mL降至44.06（4.96-255.4）IU / mL（p = 0.97，ns）。IBS-SSS在两个合规受试者中均显着降低，从245（110-480）降至110（0-140）（p <0.0001），非合规受试者从250（155-370）降至100（7-220）（ p <0.0001）。在第3周和第6周之间比较IBS-SSS，只有符合条件的受试者从155（50-355）降至110（0-140）（p = 0.005），有显着降低，相对于不合规，范围从115（35-315）到100（7-220）（p = 0.33，ns）。这些发现支持在IBS中进行外部咨询的个性化饮食干预的快速有效性和适用性。试验注册：ClinicalTrials.gov ID NCT04348760于2020年4月15日注册（已追溯注册）https://clinicaltrials.gov/show/NCT04348760